Inactive Instrument

Stem Cell Therapeutics Corp. Stock Xetra

R5W

CA8585721001

End-of-day quote Xetra
- ^EUR	-

22-01-12	TCR2 Therapeutics Appoints Chief Business and Strategy Officer	MT
21-12-13	Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis	DJ

Latest news : Stem Cell Therapeutics Corp.

22-01-12	TCR2 Therapeutics Appoints Chief Business and Strategy Officer	MT
21-12-13	Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis	DJ
21-12-13	Pfizer Eyes Enhanced Immuno-Inflammatory Disease Expertise With $6.7 Billion Arena Pharmaceuticals Takeover	MT
21-11-19	Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P Global BMI Index	CI
21-11-17	Pfizer Completes $2.22 Billion Trillium Therapeutics Acquisition	MT
21-11-17	Trillium Therapeutics Inc. Announces Executive Changes	CI
21-11-17	Trillium Therapeutics Inc. Announces Resignation of Jan Skvarka as Chief Executive Officer	CI
21-11-17	Trillium Therapeutics Inc. Announces Cessation of James Parsons as Chief Financial Officer	CI
21-11-17	Benchmark Downgrades Trillium Therapeutics to Hold From Buy	MT
21-11-17	Pfizer-Trillium Therapeutics $2.26 Billion Deal Secures Canada, US Approval	MT
21-11-17	Trillium Therapeutics Inc.(NasdaqCM:TRIL) dropped from NASDAQ Composite Index	CI
21-11-16	Pfizer Inc. completed the acquisition of remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others.	CI
21-11-12	Trillium Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI

More news

Analysts' recommendations : Stem Cell Therapeutics Corp.

21-11-17	Benchmark Downgrades Trillium Therapeutics to Hold From Buy	MT
21-08-24	Trillium Therapeutics : Benchmark Adjusts Price Target for Trillium Therapeutics to C$23.34 From C$26.41, Maintains Buy Rating	MT
21-08-24	Trillium Therapeutics : Craig-Hallum Downgrades Trillium Therapeutics to Hold From Buy	MT
21-08-24	Trillium Therapeutics : JMP Securities Downgrades Trillium Therapeutics to Market Perform From Market Outperform	MT
21-08-24	Analyst recommendations: M&S, Estee Lauder, Planet Fitness, Snowflake, Steel Dynamics...

More recommendations

Press Releases : Stem Cell Therapeutics Corp.

21-11-17	Trillium Therapeutics : Pfizer Completes Acquisition of Trillium Therapeutics - Form 8-K	PU
21-11-17	TRILLIUM THERAPEUTICS INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
21-11-16	TRILLIUM THERAPEUTICS INC. : Other Events (form 8-K)	AQ
21-11-12	Trillium: Q3 Earnings Snapshot	AQ
21-11-12	TRILLIUM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

More press releases

News in other languages : Stem Cell Therapeutics Corp.

21-12-13	Pfizer schluckt kalifornische Biotechfirma für 6,7 Mrd Dollar
21-12-13	Pfizer scommette su promettente farmaco Arena con deal da 6,7 mld $
21-11-18	Pfizer : a finalisé l'acquisition de Trillium Therapeutics
21-08-26	++ Analysen des Tages von Dow Jones Newswires (26.08.2021) +++
21-08-24	Trackinsight: La hausse des prix du pétrole et de l’or propulse les actions canadiennes

More news

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don?t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium's second SIRP?Fc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRP? as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). It focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.

Employees

Sector

More about the company